Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Ciro CelsaGiuseppe CabibboClaudia Angela Maria FulgenziSalvatore BattagliaMarco EneaBernhard ScheinerAntonio D'AlessioGiulia F ManfrediBernardo StefaniniNaoshi NishidaPeter R GalleKornelius SchulzeHenning WegeRoberta CicciaWei-Fan HsuCaterina VivaldiBrooke WietharnRyan Po-Ting LinAngelo PirozziTiziana PressianiAndrea DalbeniLeonardo A NatolaAlessandra AuriemmaCristina RigamontiMichela BurloneAlessandro ParisiYi-Hsiang HuangPei-Chang LeeCelina AngThomas U MarronMatthias PinterJaekyung CheonSamuel PhenAmit G SingalAnuhya GampaAnjana PillaiNatascha RoehlenRobert ThimmeArndt VogelNoha SororSusanna UlahannanRohini SharmaDavid SacerdotiMario PirisiLorenza RimassaChun-Yen LinAnwaar SaeedGianluca MasiMartin SchönleinJohann von FeldenMasatoshi KudoAlessio CortelliniHong Jae ChonCalogero CammàDavid James PinatoPublished in: Hepatology (Baltimore, Md.) (2024)
Hepatic decompensation identifies patients with the worst prognosis following AB and is more common in patients with baseline ALBI >1 and nonviral etiology. Effective antiviral treatment may protect from decompensation, highlighting the prognostic disadvantage of patients with nonviral etiologies and the importance of multidisciplinary management to maximize OS.